223 related articles for article (PubMed ID: 34069042)
21. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
22. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Liu N; Rowley BR; Bull CO; Schneider C; Haegebarth A; Schatz CA; Fracasso PR; Wilkie DP; Hentemann M; Wilhelm SM; Scott WJ; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2013 Nov; 12(11):2319-30. PubMed ID: 24170767
[TBL] [Abstract][Full Text] [Related]
23. (-)-4-
Song G; Lu Y; Tang L; Li M; Yin J; Chen H; Ling J
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):806-812. PubMed ID: 34694960
[TBL] [Abstract][Full Text] [Related]
24. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
25. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
26. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
Wander SA; Zhao D; Besser AH; Hong F; Wei J; Ince TA; Milikowski C; Bishopric NH; Minn AJ; Creighton CJ; Slingerland JM
Breast Cancer Res Treat; 2013 Apr; 138(2):369-81. PubMed ID: 23430223
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
[TBL] [Abstract][Full Text] [Related]
28. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
[TBL] [Abstract][Full Text] [Related]
29. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
30. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C; Ramos P; Cornille K; Bonenfant D; Fritsch C; Voshol H; Bentires-Alj M
Breast Cancer Res; 2016 Apr; 18(1):41. PubMed ID: 27048245
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Mohlin S; Hansson K; Radke K; Martinez S; Blanco-Apiricio C; Garcia-Ruiz C; Welinder C; Esfandyari J; O'Neill M; Pastor J; von Stedingk K; Bexell D
EMBO Mol Med; 2019 Aug; 11(8):e10058. PubMed ID: 31310053
[TBL] [Abstract][Full Text] [Related]
32. Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
Bullock KK; Shattuck-Brandt R; Scalise C; Luo W; Chen SC; Saleh N; Gonzalez-Ericsson PI; Garcia G; Sanders ME; Ayers GD; Yan C; Richmond A
Cancer Lett; 2024 Apr; 586():216681. PubMed ID: 38311054
[TBL] [Abstract][Full Text] [Related]
33. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Kim KJ; Kim JW; Sung JH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Kim HK; Lee KW
Sci Rep; 2020 Jul; 10(1):12308. PubMed ID: 32704014
[TBL] [Abstract][Full Text] [Related]
34. Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
Kraus D; Palasuberniam P; Chen B
Mol Cancer Ther; 2017 Nov; 16(11):2422-2431. PubMed ID: 28835385
[TBL] [Abstract][Full Text] [Related]
35. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
[TBL] [Abstract][Full Text] [Related]
37. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
38. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
39. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer.
Zhu S; Ma AH; Zhu Z; Adib E; Rao T; Li N; Ni K; Chittepu VCSR; Prabhala R; Garisto Risco J; Kwiatkowski D; Mouw K; Sonpavde G; Cheng F; Pan CX
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725212
[TBL] [Abstract][Full Text] [Related]
40. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
